Literature DB >> 21861265

Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use?

Nancy Breen1, Kathleen A Cronin, Jasmin A Tiro, Helen I Meissner, Timothy S McNeel, Susan A Sabatino, Florence K Tangka, Stephen H Taplin.   

Abstract

BACKGROUND: In 2005, mammography rates in the United States dropped nationally for the first time among age-eligible women. An increased risk of breast cancer related to hormone therapy (HT) use reported in 2002 led to a dramatic drop in its use by 2005. Because current users of HT also tend to have higher mammography rates, the authors examined whether concurrent drops in HT and mammography use were associated.
METHODS: Multivariate logistic regression was used to test for an interaction between HT use and survey year, controlling for a range of measurable factors in data from the 2000 and 2005 National Health Interview Surveys (NHIS).
RESULTS: Women ages 50 to 64 years were more likely to report a recent mammogram if they also reported more education, a usual source of care, private health insurance, any race except non-Hispanic Asian, talking with an obstetrician/gynecologist or other physician in the past 12 months, or were currently taking HT. Women aged ≥ 65 years were more likely to report a recent mammogram if they also reported younger age (ages 65-74 years), more education, a usual source of care, having Medicare Part B or other supplemental Medicare insurance, excellent health, any race except non-Hispanic Asian, talking with an obstetrician/gynecologist or other physician in the past 12 months, or were currently taking HT.
CONCLUSIONS: The change in HT use was associated with the drop in mammography use for women ages 50 to 64 years but not for women aged ≥ 65 years. NHIS data explained 70% to 80% of the change in mammography use.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21861265      PMCID: PMC3223554          DOI: 10.1002/cncr.26218

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys.

Authors:  N Breen; D K Wagener; M L Brown; W W Davis; R Ballard-Barbash
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

2.  Predictive margins with survey data.

Authors:  B I Graubard; E L Korn
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

Review 3.  Cancer screening practices from National Health Interview Surveys: past, present, and future.

Authors:  Robert A Hiatt; Carrie Klabunde; Nancy Breen; Judith Swan; Rachel Ballard-Barbash
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

4.  Evaluating organized breast cancer screening implementation: the prevention of late-stage disease?

Authors:  Stephen H Taplin; Laura Ichikawa; Diana S M Buist; Deborah Seger; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

Review 5.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials.

Authors:  Lennarth Nyström; Ingvar Andersson; Nils Bjurstam; Jan Frisell; Bo Nordenskjöld; Lars Erik Rutqvist
Journal:  Lancet       Date:  2002-03-16       Impact factor: 79.321

6.  Is screening for breast cancer with mammography justifiable?

Authors:  P C Gøtzsche; O Olsen
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

7.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.

Authors:  Ghada N Farhat; Rod Walker; Diana S M Buist; Tracy Onega; Karla Kerlikowske
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

10.  International variation in screening mammography interpretations in community-based programs.

Authors:  Joann G Elmore; Connie Y Nakano; Thomas D Koepsell; Laurel M Desnick; Carl J D'Orsi; David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

View more
  5 in total

1.  The "Welcome to Medicare" visit: a missed opportunity for cancer screening among women?

Authors:  Ramzi G Salloum; Gail A Jensen; Andrea K Biddle
Journal:  J Womens Health (Larchmt)       Date:  2012-11-12       Impact factor: 2.681

2.  Determinants of Cancer Screening Disparities Among Asian Americans: A Systematic Review of Public Health Surveys.

Authors:  Jungmi Jun; Xiaoli Nan
Journal:  J Cancer Educ       Date:  2018-08       Impact factor: 2.037

Review 3.  Opportunities and challenges for the use of large-scale surveys in public health research: a comparison of the assessment of cancer screening behaviors.

Authors:  Jada G Hamilton; Nancy Breen; Carrie N Klabunde; Richard P Moser; Bryan Leyva; Erica S Breslau; Sarah C Kobrin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-09       Impact factor: 4.254

4.  The cost of cancer-related physician services to Medicare.

Authors:  Sean Maroongroge; Simon P Kim; Sarah Mougalian; Kimberly Johung; Roy H Decker; Pamela R Soulos; Jessica B Long; Cary P Gross; James B Yu
Journal:  Yale J Biol Med       Date:  2015-06-01

5.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.

Authors: 
Journal:  Lancet       Date:  2019-08-29       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.